SCHEMBL434540

SCHEMBL434540

O=C(O)CCCCCCCCCF

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.71
LMNA P02545 3/20 0.71
NFKB1 P19838 2/20 0.71
PMP22 Q01453 1/20 0.71
ALDH1A1 P00352 3/20 0.62
MEN1 O00255 2/20 0.62
ALOX15 P16050 2/20 0.62
KMT2A Q03164 2/20 0.62
PLG P00747 1/20 0.62
THRB P10828 1/20 0.62
SLC6A2 P23975 1/20 0.62
RECQL P46063 1/20 0.62
SLC6A3 Q01959 1/20 0.62
GPR84 Q9NQS5 8/20 0.57
FFAR1 O14842 2/20 0.57
FFAR4 Q5NUL3 2/20 0.57
CYP2D6 P10635 1/20 0.57
SLC22A6 Q4U2R8 2/20 0.56
PPARG P37231 6/20 0.55
PPARD Q03181 6/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3408123 1.00 TSHR (0.71) TSHRLMNANFKB1PMP22ALDH1A1
SCHEMBL6575728 1.00 TSHR (0.71) TSHRLMNANFKB1PMP22ALDH1A1
SCHEMBL10004661 1.00 TSHR (0.71) TSHRLMNANFKB1PMP22ALDH1A1
SCHEMBL4609065 1.00 TSHR (0.71) TSHRLMNANFKB1PMP22ALDH1A1
SCHEMBL8864071 1.00 TSHR (0.71) TSHRLMNANFKB1PMP22ALDH1A1
SCHEMBL7221658 1.00 TSHR (0.71) TSHRLMNANFKB1PMP22ALDH1A1
SCHEMBL1706463 1.00
SCHEMBL9096720 1.00 TSHR (0.71) TSHRLMNANFKB1PMP22ALDH1A1
SCHEMBL8864033 1.00 TSHR (0.71) TSHRLMNANFKB1PMP22ALDH1A1
SCHEMBL28985038 1.00 TSHR (0.71) TSHRLMNANFKB1PMP22ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5897940-A Ink jet transparencies XEROX CORPORATION (US) 1999-04-27 US claimed
EP-4739652-A1 LIPIDS AND COMPOSITIONS THEREOF Kernal Biologics, Inc. (US) 2026-05-13 EP disclosed
US-20260116845-A1 LIPIDS AND COMPOSITIONS THEREOF KERNAL BIOLOGICS INC (US) 2026-04-30 US disclosed
CN-119881046-A Electrochemical molecular imprinting sensor and preparation method and application thereof 中国环境监测总站 2025-04-25 CN disclosed
WO-2025010290-A1 LIPIDS AND COMPOSITIONS THEREOF KERNAL BIOLOGICS, INC. (US) 2025-01-09 WO disclosed
CN-118994898-A Toughened polyamide composite material and preparation method and application thereof 浙江天开实业有限公司 2024-11-22 CN disclosed
CN-118533933-B Perfluoro caprylic acid anti-interference electrochemical molecularly imprinted sensor and preparation method and application thereof 同济大学 2024-11-15 CN disclosed
CN-115974713-B Fluorine-containing compound, preparation method and compound containing fluorine-containing compound 中国科学技术大学 2024-10-01 CN disclosed
US-12076705-B2 Capture of fluorinated carbon compounds THE UNIVERSITY OF QUEENSLAND (AU) 2024-09-03 US disclosed
CN-118533933-A Perfluoro caprylic acid anti-interference electrochemical molecularly imprinted sensor and preparation method and application thereof 同济大学 2024-08-23 CN disclosed
EP-2327403-A2 Pharmaceutical combinations of at least two bronchodilators Cipla Limited (IN) 2011-06-01 EP disclosed
US-20100063016-A1 Pharmaceutical Combinations CIPLA LIMITED (IN) 2010-03-11 US disclosed
EP-2124915-A2 PHARMACEUTICAL COMBINATIONS OF AT LEAST TWO BRONCHODILATORS OR OF A BRONCHODILATOR WITH A CORTICOSTEROID Cipla Limited (IN) 2009-12-02 EP disclosed
WO-2008102128-A2 PHARMACEUTICAL COMBINATIONS OF AT LEAST TWO BRONCHODILATORS OR OF A BRONCHODILATOR WITH A CORTICOSTEROID CIPLA LIMITED (IN) 2008-08-28 WO disclosed
US-5897940-A Ink jet transparencies XEROX CORPORATION (US) 1999-04-27 US disclosed
US-5744273-A Laminatable backing substrates containing fluoro compounds for improved toner flow XEROX CORPORATION (US) 1998-04-28 US disclosed
WO-1998013069-A2 FLUORINATED COPOLYMERIC PHARMACEUTICAL ADJUNCTS SUPRATEK PHARMA, INC. (CA) 1998-04-02 WO disclosed
WO-1995014132-A1 COMPOSITION AND METHOD FOR TREATING SUBSTRATES TO REDUCE ELECTROSTATIC CHARGE AND RESULTANT ARTICLE HENKEL CORPORATION (US) 1995-05-26 WO disclosed
EP-0348462-A4 SURFACE MODIFIED OPTICAL LENS AND METHOD OF SURFACE MODIFICATION. IOPTEX RES INC (US) 1990-07-03 EP disclosed
WO-1989004330-A1 SURFACE MODIFIED OPTICAL LENS AND METHOD OF SURFACE MODIFICATION IOPTEX RESEARCH, INC. (US) 1989-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116845-A1 LIPIDS AND COMPOSITIONS THEREOF LIPC, LIPA, NPC1L1 TSHR 1603/4885LMNA 78/4885NFKB1 4353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.